Twilight Litaka Pharma Limited
Regd. Office : Himalaya Estate, 16-A Shivajinagar, Pune 411 005

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2012

(Rs.in Lac)

S No.	Particulars	Quarter Ended			Financial Year ended	
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
		31.03.2012	31.12.2011	31.03.2011	31.03.2012	31.03.2011
1	a. Net Sales / Income From Operations	17860.09	18672.48	16174.17	72953.71	65678.11
	b. Other Operating Income		-	-		-
2	Expenditure					
	a Increase/decrease in stock in trade & WIP	-141.08	23.17	-70.74	-281.24	-778.19
	b Consumption of Raw material	1505.18	13515.24	11435.51	40055.87	46721.12
	c Purchase of traded goods.	12931.22	536.95	1084.56	16402.58	4643.94
	d Employee cost	452.78	538.05	448.56	1982.39	1767.93
	e Depreciation	127.68	133.48	88.77	510.25	364.87
	f Other expenditure	1224.12	1240.54	1005.78	4661.34	3806.45
	g Expenditure (a to f)	16099.91	15987.43	13992.44	63331.20	56526.12
3	**Profit from Operations before Other Income, Interest and Exceptional Items (1-2)**	1760.18	2685.05	2181.73	9622.51	9151.99
4	Other Income	255.11	13.88	147.62	332.60	373.26
5	**Profit before Interest & Exceptional Items (3+4)**	2015.29	2698.93	2329.35	9955.11	9525.25
6	Interest	1232.12	1283.84	1103.03	4698.28	3187.22
7	**Profit after Interest, but before Exceptional Items (5-6)**	783.17	1415.09	1226.32	5256.83	6338.03
8	Exceptional Items	-	-	-	-	-
9	**Profit from Ordinary Activities before tax (7+8)**	783.17	1415.09	1226.32	5256.83	6338.03
10	Tax Expenses	90.00	477.00	330.00	1360.00	1393.57
11	**Profit from Ordinary Activities after tax (9-10)**	693.17	938.09	896.32	3896.83	4944.46
12	Extraordinary items (net of tax expense)	-	-	-	-	-
13	**Net Profit for the period**	693.17	938.09	896.32	3896.83	4944.46
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1239.06	1239.06	1064.06	1239.06	1064.06
15	Reserve excluding revaluation reserves	19531.03	18837.86	13160.64	19531.03	12695.21
16	Earning per share (EPS)					
	a. Basic and diluted EPS before extraordinary items for the period	*2.75	*3.74	*4.21	*16.19	*23.23
	b. Basic and diluted EPS after extraordinary items for the period.	*2.75	*3.74	*4.21	*16.19	*23.23
17	Aggregate of non promoter shareholding					
	number of shares	23520796	23225796	12516051	23520796	12516051
	percentage of shareholding	94.91	93.72	58.81	94.91	58.81
18	Promoters and Promoters Group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	1236247	1531247	8440541	1236247	8440541
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	98.07	98.44	96.29	98.07	96.29
	- Percentage of shares (as % to the total share capital of the Company)	4.99	6.18	39.66	4.99	39.66
	b) Non Encumbered					
	- Number of shares	24242	24242	324693	24242	324693
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	1.93	1.56	3.71	1.93	3.71
	- Percentage of shares (as % to the total share capital of the Company)	0.10	0.10	1.53	0.10	1.53

* not annualised

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 15th May, 2012.

2] Provision for Tax includes Current Year Tax and Deferred Tax .

3] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) ""Segment Reporting" is considered to be the only business segment.

4] Between 10th June,11 to 16th June,11 the company has alloted 35,00,000 Equity Shares of Rs.5/- each at Rs. 86/- per Equity Shares as per Terms of issue of 35,00,000 Convertible Warrants, which were listed on BSE and NSE.

5] The financial results for the quarter ended 31st March,2012 of the company are prepared on standalone basis.

6] The above results were subjected to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.

7) On receipt of appoval from Bankers of the company, the dividend which was declared in the last Annual General Meeting held on 29th September,2011 will be paid to the shareholders of the company

8] Previous year's figures have been regrouped and rearranged wherever necessary.

9] During the current quarter, Ten (10) Investor complaints were received. There were five (5) investor complaint pending at the beginning of the quarter and Thirteen (13) Iinvestor complaints were pending at the end of the quarter.

For TWILIGHT LITAKA PHARMA LIMITED

GOPAL RAMOURTI
Managing Director

Place : Pune
Date : 15th May, 2012

TWILIGHT LITAKA PHARMA LTD. PUNE